DENOSUMAB IN THE TREATMENT OF OSTEOPOROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS (RESULTS OF 2-YEAR FOLLOW-UP)
About the Authors
O. V. Dobrovolskaya
Ministry of Science and Higher Education;
Research Institute of Rheumatology named after V.A. Nasonova
Russian Federation
Russian Federation
Moscow
P. S. Kovalenko
Ministry of Science and Higher Education;
Research Institute of Rheumatology named after V.A. Nasonova
Russian Federation
Russian Federation
Moscow
N. V. Demin
Ministry of Science and Higher Education;
Research Institute of Rheumatology named after V.A. Nasonova
Russian Federation
Russian Federation
Moscow
N. V. Toroptsova
Ministry of Science and Higher Education;
Research Institute of Rheumatology named after V.A. Nasonova
Russian Federation
Russian Federation
Moscow
I. S. Dydykina
Ministry of Science and Higher Education;
Research Institute of Rheumatology named after V.A. Nasonova
Russian Federation
Russian Federation
Moscow
O. A. Nikitinskaya
Ministry of Science and Higher Education;
Research Institute of Rheumatology named after V.A. Nasonova
Russian Federation
Russian Federation
Moscow
E. L. Nasonov
Ministry of Science and Higher Education;
Research Institute of Rheumatology named after V.A. Nasonova
Russian Federation
Russian Federation
Moscow
Review
For citations:
Dobrovolskaya O.V., Kovalenko P.S., Demin N.V., Toroptsova N.V., Dydykina I.S., Nikitinskaya O.A., Nasonov E.L. DENOSUMAB IN THE TREATMENT OF OSTEOPOROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS (RESULTS OF 2-YEAR FOLLOW-UP). Osteoporosis and Bone Diseases. 2020;23(1):107. (In Russ.)
Views:
188
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
